Literature DB >> 15210898

Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.

G Cavaletti1, A Beronio, L Reni, E Ghiglione, A Schenone, C Briani, G Zara, D Cocito, G Isoardo, P Ciaramitaro, R Plasmati, F Pastorelli, M Frigo, M Piatti, M Carpo.   

Abstract

The clinical and neurophysiologic data from 65 patients taking thalidomide were reviewed. Thalidomide sensory neurotoxicity was found to be cumulative dose dependent but occurs only when the total dose is relatively high (>20 g). The risk of developing sensory neuropathy is around 10% below this threshold but increases with higher doses.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15210898     DOI： 10.1212/wnl.62.12.2291

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  25 in total

Review 1.  Neurologic toxicities of cancer therapies.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Long-term therapy with bevacizumab in a patient with Glanzmann's thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions.

Authors:  Raphael Marlu; J Barthelon; A Durand; N Mathieu; C Barro; V Granger; A Tatu; G Pernod; B Polack; B Bonaz
Journal:  Am J Gastroenterol       Date:  2015-02       Impact factor: 10.864

Review 3.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 4.  Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith
Journal:  Semin Oncol Nurs       Date:  2019-04-30       Impact factor: 2.315

5.  Comparative neurotoxicity screening in human iPSC-derived neural stem cells, neurons and astrocytes.

Authors:  Ying Pei; Jun Peng; Mamta Behl; Nisha S Sipes; Keith R Shockley; Mahendra S Rao; Raymond R Tice; Xianmin Zeng
Journal:  Brain Res       Date:  2015-08-05       Impact factor: 3.252

6.  Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.

Authors:  Elijah W Stommel; Jeffrey A Cohen; Camilo E Fadul; Christopher H Cogbill; David J Graber; Linda Kingman; Todd Mackenzie; Jacqueline Y Channon Smith; Brent T Harris
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

Review 7.  Neurological adverse effects caused by cytotoxic and targeted therapies.

Authors:  David Schiff; Patrick Y Wen; Martin J van den Bent
Journal:  Nat Rev Clin Oncol       Date:  2009-08-25       Impact factor: 66.675

Review 8.  Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding.

Authors:  Juergen Bauditz; Herbert Lochs
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

Review 9.  New therapies in multiple myeloma.

Authors:  F Merchionne; F Perosa; F Dammacco
Journal:  Clin Exp Med       Date:  2007-10-03       Impact factor: 3.984

10.  Front line treatment of elderly multiple myeloma in the era of novel agents.

Authors:  Marie-Dominique Venon; Aldo M Roccaro; Julie Gay; Anne-Sophie Moreau; Remy Dulery; Thierry Facon; Irene M Ghobrial; Xavier Leleu
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.